TRIUMEQ主治什么？

Triumeq () is a drug for the treatment of AIDS (HIV). Triumeq (TRIUMEQ) is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier, and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

HIV is a virus that attacks the body's immune system. It takes the most important CD4 T lymphocytes in the human immune system as its main attack target, destroys these cells in large quantities, and causes the human body to lose its immune function. Therefore, the human body is susceptible to various diseases, and malignant tumors can occur, with a high mortality rate. The average incubation period of HIV in the human body is 8 to 9 years.

In 2018, GSK announced the launch of the integrase DTG (TRIUMEQ) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. TRIUMEQ uses DTG, an integrase inhibitor, as the core drug, and is paired with a treatment plan of two backbone drugs, abacavir and lamivudine, and is made into a single-tablet treatment for promotion, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

For adults and adolescents (weight at least 40 kg), the recommended dose of TRIUMEQ is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced.

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or dose adjustments made, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines.